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The haemodynamic changes of pregnancy can have a negative
impact on maternal cardiac health, especially in women with pre-
existing cardiac disease. In the most recent Confidential Inquiries
into Maternal Mortality in the United Kingdom, heart disease
was found to be the most common indirect cause of maternal
death during pregnancy.1 Pregnancy counselling and management
for women with heart disease is being increasingly recognized as
an important aspect of their overall cardiac care. With increasing
awareness, there has been a growing body of research focused
on pregnancy outcomes and risk stratification. There have also
been new initiatives to improve clinical care, such as the 2011
European Society of Cardiology (ESC) guidelines on the manage-
ment of cardiovascular disease during pregnancy.2 While our
current understanding of pregnancy risk assessment and manage-
ment has improved over the past 20 years, many questions can
only be answered by collaborative efforts.
Roos-Hesselink and colleagues have now presented the first
report of their multicentre, multinational Registry On Pregnancy
and Cardiac disease (ROPAC) registry, supported by the ESC.3
The study is important because it provides a global perspective on
pregnancy in women with heart disease. It included 1321 pregnan-
cies in women from 28 countries, the majority of which were devel-
oped countries (86%) in Europe and North America. Most women
from developed countries had underlying congenital heart disease
(74%). In contrast, valvular heart disease was the predominant
underlying cardiac condition (72%) in pregnancies reported from
women in developing countries where rheumatic heart disease
remains endemic. The study reports high rates of adverse maternal
cardiac events during pregnancy including increased risk of maternal
deaths. Hospital admission for cardiac reasons complicated 15% of
all pregnancies, primarily for treatment of heart failure. Similarly
high event rates of adverse maternal cardiac events have been
reported by other groups (Figure 1).4,5 Collectively, these studies
highlight the need to identify women at highest risk and to
develop care models to improve outcomes. Because maternal
deaths at any one centre are relative rare, largemulticentre registries
such as this are necessary to study mortality outcomes. Although
rare, maternal mortality (13/1321 pregnancies, 7 due to heart
failure, 3 due to thrombo-embolic events, and 3 due to non-
cardiac-related sepsis) was much more likely to occur in women
with heart disease compared with the general population. While
there are a number of risk scores for predicting adverse pregnancy
outcomes in women with heart disease, this study externally vali-
dated the model proposed by the British Working Group, demon-
strating its utility in predicting maternal mortality, the occurrence
of heart failure, and fetal death.2,6
Cardiac disease in pregnant women will probably be increasingly
encountered in medical practice. With advances in cardiac surgery
and improved childhood survival, there is a growing population of
young women of childbearing age with congenital heart disease.7,8
Most of these women, particularly those with lesions of moderate
or great complexity, have residua or sequelae that increase their
risk of cardiovascular complications during pregnancy. Rheumatic
heart disease, rare in developed countries, remains a major health
problem in developing and underdeveloped countries. Women
with rheumatic valve lesions such as mitral stenosis tolerate preg-
nancy poorly.9 The prevalence of ischaemic heart disease complicat-
ing pregnancies is increasing,1,10,11 perhaps related to trends in
western societies of having children later in life and associated
higher rates of cardiovascular risk factors in this older cohort.
Further increases may occur with increasing assisted fertilization in
older women. With this growing and evolving population, ongoing
education of health care providers and patients is important.
Pre-conception counselling allows women to make informed
pregnancy decisions, and risk stratification tools can be helpful to
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predict pregnancy risk. A number of risk stratification tools have
been proposed to identify those women at highest risk.4–6,12 For
some cardiac lesions, there is very little risk of adverse cardiac
events during pregnancy, no special precautions are required
during pregnancy, and women need nothing more than reassur-
ance. In other cases, pregnancy poses a prohibitive risk and
women need to be educated about the need to avoid pregnancy
and about safe contraception options. Unfortunately, a number
of groups have reported that women with heart disease often
have inaccurate knowledge of pregnancy risk.13,14 Once pregnant,
women identified as intermediate or high risk should receive coor-
dinated care, with input from a cardiologist with exptertise in preg-
nancy and heart disease, a high-risk obstetrician, and an obstetrical
anaesthetist. To date, few studies have addressed delivery of care
or quality of care in this high-risk population.
The ROPAC registry is likely to have many roles. As the registry
increases in size, rare cardiac conditions or outcomes (such as ma-
ternal, fetal, or neonatal mortality) can be studied in more detail.
The registry data can be used for validating and refining existing
risk stratification scoring models or identifying novel risk markers
derived from smaller mechanistic studies. The registry data can
help to determine and compare regional treatment strategies and
outcomes. Other parameters, such as healthcare costs, could be
studied. The ROPAC registry is an important initiative that will
help to improve the care of pregnant women with heart disease.
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Figure 1 Risk of heart failure, other non-fatal adverse cardio-
vascular events, and maternal death in three large multicentre
studies of pregnancy outcomes in women with heart disease.
*The CARPREG study and the ROPAC registry include women
with congenital and acquired heart disease. **The ZAHARA
study included only women with congenital heart disease.
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